Provided by Tiger Trade Technology Pte. Ltd.

Alumis Inc.

24.17
+1.315.73%
Post-market: 23.83-0.3400-1.41%19:30 EDT
Volume:934.81K
Turnover:22.12M
Market Cap:3.12B
PE:-6.36
High:24.70
Open:22.98
Low:22.21
Close:22.86
52wk High:31.35
52wk Low:3.76
Shares:129.00M
Float Shares:109.67M
Volume Ratio:1.01
T/O Rate:0.85%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8005
EPS(LYR):-2.8616
ROE:-93.65%
ROA:-45.34%
PB:6.90
PE(LYR):-8.45

Loading ...

Company Profile

Company Name:
Alumis Inc.
Exchange:
NASDAQ
Establishment Date:
2021
Employees:
238
Office Location:
280 East Grand Avenue,South San Francisco,California,United States
Zip Code:
94080
Fax:
- -
Introduction:
Alumis Inc. was incorporated on January 29, 2021, as a Delaware corporation. It is a clinical-stage biopharmaceutical company initially focused on developing two tyrosine kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor designed to achieve maximal target inhibition, and A-005, a CNS-penetrant molecule. The company's mission is to significantly improve patients' lives by replacing broad immunosuppression with targeted therapies.

Directors

Name
Position
Martin Babler
Chairman of the Board and Chief Executive Officer and Director and President
Alan B. Colowick
Director
James B. Tananbaum
Director
Lynn Tetrault
Director
C. Patrick Machado
Director
Sapna Srivastava
Director
Srinivas Akkaraju
Director
Zhengbin Yao
Director

Shareholders

Name
Position
Martin Babler
Chairman of the Board and Chief Executive Officer and Director and President
John Schroer
Chief Financial Officer
David M. Goldstein
Chief Scientific Officer
Jörn Drappa
Chief Medical Officer
Mark Bradley
Chief Development Officer
Roy Hardiman
Chief Business and Strategy Officer
Sanam Pangali
Chief Legal Officer and Corporate Secretary